Perrigo, Hikma, Mallinckrodt Bid for Boehringer’s Roxane Labs

Source: Bloomberg

Jul 01, 2015

Dublin-based drugmakers Mallinckrodt and Perrigo as well as London-based Hikma Pharma are all potential buyers for Boehringer Ingelheim’s Roxane Labs business in the U.S., according to Bloomberg sources.

The generic pharmaceutical unit could sell for a potential $2.2 billion -- or the German drugmaker may still choose to keep the asset.

Sources say a decision could be made within weeks.

According to Bidness Etc,  a Perrigo-Roxane merger would create an additional hurdle in Mylan’s quest to buy Perrigo, as the acquisition would enable Perrigo to expand its platform into generics while remaining a standalone entity. This would be good news for Teva, as Mylan desperately needs the Perrigo merger to defend against Teva's unsolicited $82 per share takeover offer.

Read the Bloomberg article

Return to the Pharma Mfg Newsletter

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments